Evidence map›Paper›PMID 39636431›Full record

ArticleMolecular and cellular biochemistry2025

Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy.

Ge Yu, Abiyasi Nanding

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Salidroside in heavy metal toxicity: a mechanistic review of antioxidant, anti-inflammatory, and anti-apoptotic pathways.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ge YuDepartment of Gynecology, Harbin Medical University Cancer Hospital, NO.150 Haping Road, Nangang District, Harbin, Heilongjiang Province, China.
Abiyasi NandingDepartment of Pathology, Harbin Medical University Cancer Hospital, NO.150 Haping Road, Nangang District, Harbin, Heilongjiang Province, China. abiyasi001@163.com.

Funding

BeiJing Heart To Heart Foundation HXXT2022ktyj002Haiyan Foundation of Cancer Hospital Affiliated to Harbin Medical University JJMs2022-08Institute of Science and Technology, National Health Commission of People's Republic of China 2021HX01408
6 · The paper itself

Abstract

Cisplatin (DDP) resistance significantly affects the survival rate of patients with ovarian cancer (OC). Autophagy is recognized as a common cause of resistance to DDP. This study aimed to investigate the impact of salidroside on OC progression and explore its potential regulatory effects on DDP resistance and autophagy. A DDP-resistant A2780 (A2780/DDP) cell line was induced by exposure to increasing DDP concentrations. The protein levels of autophagy proteins (p62, Beclin-1, ATG5, and LC3 II/LC3 I), apoptosis proteins (cleaved caspase-3 and cleaved caspase-9), and PI3K/AKT/mTOR pathway were determined by western blotting. Autophagic vacuoles in cells were observed with LC3 dyeing with confocal fluorescent microscopy. Cell viability and apoptosis were evaluated by cell counting kit-8 assays and flow cytometry. RT-qPCR was conducted to measure the relative levels of various lncRNAs in A2780 or A2780/DDP cells. A xenograft model was established by subcutaneous injection of 1 × 10

Indexed as

AutophagyCisplatinDrug Resistance, NeoplasmGlucosidesOvarian NeoplasmsPhenolsRNA, Long NoncodingAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, NudeSignal TransductionXenograft Model Antitumor AssaysCisplatinGlucosidesPhenolsrhodiolosideRNA, Long NoncodingAutophagyCisplatinCRNDEOvarian cancerResistanceSalidroside

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.